These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38958840)

  • 21. Pharmacology and toxicology of eteplirsen and SRP-5051 for DMD exon 51 skipping: an update.
    Sheikh O; Yokota T
    Arch Toxicol; 2022 Jan; 96(1):1-9. PubMed ID: 34797383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measuring Duchenne muscular dystrophy impact: development of a proxy-reported measure derived from PROMIS item banks.
    Schwartz CE; Stark RB; Cella D; Borowiec K; Gooch KL; Audhya IF
    Orphanet J Rare Dis; 2021 Nov; 16(1):487. PubMed ID: 34809687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eteplirsen: First Global Approval.
    Syed YY
    Drugs; 2016 Nov; 76(17):1699-1704. PubMed ID: 27807823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.
    Garegnani L; Hyland M; Roson Rodriguez P; Escobar Liquitay CME; Franco JV
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013720. PubMed ID: 34748221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.
    Garegnani L; Hyland M; Roson Rodriguez P; Escobar Liquitay CM; Franco JV
    Cochrane Database Syst Rev; 2021 Dec; 12(12):CD013720. PubMed ID: 34850383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Participation and quality of life in children with Duchenne muscular dystrophy using the International Classification of Functioning, Disability, and Health.
    Bendixen RM; Senesac C; Lott DJ; Vandenborne K
    Health Qual Life Outcomes; 2012 May; 10():43. PubMed ID: 22545870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment.
    Mitelman O; Abdel-Hamid HZ; Byrne BJ; Connolly AM; Heydemann P; Proud C; Shieh PB; Wagner KR; Dugar A; Santra S; Signorovitch J; Goemans N; ; McDonald CM; ; Mercuri E; ; Mendell JR
    J Neuromuscul Dis; 2022; 9(1):39-52. PubMed ID: 34420980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a Clinical Global Impression of Change (CGI-C) and a Caregiver Global Impression of Change (CaGI-C) measure for ambulant individuals with Duchenne muscular dystrophy.
    Staunton H; Trennery C; Arbuckle R; Guridi M; Zhuravleva E; Furlong P; Fischer R; Hall R
    Health Qual Life Outcomes; 2021 Jul; 19(1):184. PubMed ID: 34311756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reliability and validity of the Thai version of the Pediatric Quality of Life inventory™ 3.0 Duchenne Muscular Dystrophy module in Thai children with Duchenne Muscular Dystrophy.
    Thongsing A; Likasitwattanakul S; Sanmaneechai O
    Health Qual Life Outcomes; 2019 May; 17(1):76. PubMed ID: 31046775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The PedsQL in pediatric patients with Duchenne muscular dystrophy: feasibility, reliability, and validity of the Pediatric Quality of Life Inventory Neuromuscular Module and Generic Core Scales.
    Davis SE; Hynan LS; Limbers CA; Andersen CM; Greene MC; Varni JW; Iannaccone ST
    J Clin Neuromuscul Dis; 2010 Mar; 11(3):97-109. PubMed ID: 20215981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Golodirsen for Duchenne muscular dystrophy.
    Anwar S; Yokota T
    Drugs Today (Barc); 2020 Aug; 56(8):491-504. PubMed ID: 33025945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The experience of parents of adult sons with Duchenne muscular dystrophy regarding their prolonged roles as primary caregivers: a serial qualitative study.
    Yamaguchi M; Sonoda E; Suzuki M
    Disabil Rehabil; 2019 Apr; 41(7):746-752. PubMed ID: 29172756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Respiratory muscle training in children and adults with neuromuscular disease.
    Silva IS; Pedrosa R; Azevedo IG; Forbes AM; Fregonezi GA; Dourado Junior ME; Lima SR; Ferreira GM
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011711. PubMed ID: 31487757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psychometric properties of the Zarit Caregiver Burden Interview administered to caregivers to patients with Duchenne muscular dystrophy: a Rasch analysis.
    Landfeldt E; Mayhew A; Straub V; Bushby K; Lochmüller H; Lindgren P
    Disabil Rehabil; 2019 Apr; 41(8):966-973. PubMed ID: 29254382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Labor market participation and productivity costs for female caregivers of minor male children with Duchenne and Becker muscular dystrophies.
    Soelaeman RH; Smith MG; Sahay K; Tilford JM; Goodenough D; Paramsothy P; Ouyang L; Oleszek J; Grosse SD
    Muscle Nerve; 2021 Dec; 64(6):717-725. PubMed ID: 34605048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. "You Take This Day by Day, Come What May": A Qualitative Study of the Psychosocial Impacts of Living with Duchenne Muscular Dystrophy.
    Bever A; Audhya I; Szabo SM; Mickle A; Feeny D; Malone D; Neumann P; Iannaccone S; Gooch K
    Adv Ther; 2024 Jun; 41(6):2460-2476. PubMed ID: 38709395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis.
    Shimizu-Motohashi Y; Murakami T; Kimura E; Komaki H; Watanabe N
    Orphanet J Rare Dis; 2018 Jun; 13(1):93. PubMed ID: 29907124
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.